Complete Sustained Response of a Refractory, Post-Transplantation, Large B-Cell Lymphoma to an Anti-CD22 Immunotoxin
Authors: Adrian M. Senderowicz, Ellen S Vitetta, Donna Headlee, Victor Ghetie, Jonathan W. Uhr, William D. Figg, Richard M. Lush, Maryalice Stetler-Stevenson, Glenn Kershaw, Douglas W. Kingma, Elaine S. Jaffe, Edward A. Sausville
Journal: Annals of Internal Medicine (1997)

Brief Communications1 June 1997Complete Sustained Response of a Refractory, Post-Transplantation, Large B-Cell Lymphoma to an Anti-CD22 ImmunotoxinAdrian M. Senderowicz, MD, Ellen Vitetta, PhD, Donna Headlee, RN, Victor Ghetie, PhD, Jonathan W. Uhr, MD, William D. Figg, PharmD, Richard M. Lush, PhD, Maryalice Stetler-Stevenson, MD, PhD, Glenn Kershaw, MD, Douglas W. Kingma, MD, Elaine S. Jaffe, MD, and Edward A. Sausville, MD, PhDAdrian M. Senderowicz, MDFrom the National Cancer Institute, National Institutes of Health, Bethesda, Maryland; University of Massachusetts Medical Center, Worcester, Massachusetts; and University of Texas Southwestern Medical Center, Dallas, Texas., Ellen Vitetta, PhDFrom the National Cancer Institute, National Institutes of Health, Bethesda, Maryland; University of Massachusetts Medical Center, Worcester, Massachusetts; and University of Texas Southwestern Medical Center, Dallas, Texas., Donna Headlee, RNFrom the National Cancer Institute, National Institutes of Health, Bethesda, Maryland; University of Massachusetts Medical Center, Worcester, Massachusetts; and University of Texas Southwestern Medical Center, Dallas, Texas., Victor Ghetie, PhDFrom the National Cancer Institute, National Institutes of Health, Bethesda, Maryland; University of Massachusetts Medical Center, Worcester, Massachusetts; and University of Texas Southwestern Medical Center, Dallas, Texas., Jonathan W. Uhr, MDFrom the National Cancer Institute, National Institutes of Health, Bethesda, Maryland; University of Massachusetts Medical Center, Worcester, Massachusetts; and University of Texas Southwestern Medical Center, Dallas, Texas., William D. Figg, PharmDFrom the National Cancer Institute, National Institutes of Health, Bethesda, Maryland; University of Massachusetts Medical Center, Worcester, Massachusetts; and University of Texas Southwestern Medical Center, Dallas, Texas., Richard M. Lush, PhDFrom the National Cancer Institute, National Institutes of Health, Bethesda, Maryland; University of Massachusetts Medical Center, Worcester, Massachusetts; and University of Texas Southwestern Medical Center, Dallas, Texas., Maryalice Stetler-Stevenson, MD, PhDFrom the National Cancer Institute, National Institutes of Health, Bethesda, Maryland; University of Massachusetts Medical Center, Worcester, Massachusetts; and University of Texas Southwestern Medical Center, Dallas, Texas., Glenn Kershaw, MDFrom the National Cancer Institute, National Institutes of Health, Bethesda, Maryland; University of Massachusetts Medical Center, Worcester, Massachusetts; and University of Texas Southwestern Medical Center, Dallas, Texas., Douglas W. Kingma, MDFrom the National Cancer Institute, National Institutes of Health, Bethesda, Maryland; University of Massachusetts Medical Center, Worcester, Massachusetts; and University of Texas Southwestern Medical Center, Dallas, Texas., Elaine S. Jaffe, MDFrom the National Cancer Institute, National Institutes of Health, Bethesda, Maryland; University of Massachusetts Medical Center, Worcester, Massachusetts; and University of Texas Southwestern Medical Center, Dallas, Texas., and Edward A. Sausville, MD, PhDFrom the National Cancer Institute, National Institutes of Health, Bethesda, Maryland; University of Massachusetts Medical Center, Worcester, Massachusetts; and University of Texas Southwestern Medical Center, Dallas, Texas.Author, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-126-11-199706010-00005 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail GlossaryCD19, CD20, CD21, CD22: B-cell surface markers frequently expressed on the surface of B-cell tumors. The immunotoxin used in our patient is directed against CD22.EBER-1: Epstein-Barr encoded RNA.Immunotoxin: A drug formed by chemical linkage of an antibody to a toxin.RFB4-dgA: The immunotoxin used in our patient; it consists of the murine monoclonal antibody RFB4, which is linked to the deglycosylated A-chain of ricin, a plant toxin.Vascular leak syndrome: A side effect of immunotoxin treatment that consists of nontargeted damage to endothelial cells and manifests as hypoalbuminemia and edema in its mild form.Transplant recipients have ...References1. Morrison VA, Dunn DL, Manivel JC, Gajl-Peczalska KJ, Peterson BA. Clinical characteristics of post-transplant lymphoproliferative disorders. Am J Med. 1994; 97:14-24. Google Scholar2. Hanto DW. Classification of Epstein-Barr virus-associated posttransplant lymphoproliferative diseases: implications for understanding their pathogenesis and developing rational treatment strategies. Annu Rev Med. 1995; 46:381-94. Google Scholar3. Knowles DM, Cesarman E, Chadburn A, Frizzera G, Chen J, Rose EA, et al. Correlative morphologic and molecular genetic analysis demonstrates three distinct categories of posttransplantation lymphoproliferative disorders. Blood. 1995; 85:552-65. Google Scholar4. Sausville EA. Targeted toxins. In: Bertino J, ed. Encyclopedia of Cancer. San Diego: Academic Pr; 1997:1703-14. Google Scholar5. Harris NL, Jaffe ES, Stein H, Banks PM, Chan JK, Cleary ML, et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood. 1994; 84:1361-92. Google Scholar6. Fisher RI, Gaynor ER, Dahlberg S, Oken MM, Grogan TM, Mize EM, et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med. 1993; 328:1002-6. Google Scholar7. Sundeen J, Longo D, Jaffe E. CD5 expression in B-cell small lymphocytic malignancies. Correlations with clinical presentation and sites of disease. Am J Surg Pathol. 1992; 16:130-7. Google Scholar8. Kingma DW, Medeiros LJ, Barletta J, Raffeld M, Mann RB, Ambinder RF, et al. Epstein-Barr virus is infrequently identified in non-Hodgkin's lymphomas associated with Hodgkin's disease. Am J Surg Pathol. 1994; 18:48-61. Google Scholar9. Sander CA, Yano T, Clark HM, Harris C, Longo DL, Jaffe ES, et al. p53 mutation is associated with progression in follicular lymphomas. Blood. 1993; 82:1994-2004. Google Scholar10. Sausville EA, Headlee D, Stetler-Stevenson M, Jaffe ES, Solomon D, Figg WD, et al. Continuous infusion of the anti-CD22 immunotoxin IgG-RFB4-SMPT-dgA in patients with B-cell lymphoma: a phase I study. Blood. 1995; 85:3457-65. Google Scholar11. Amlot PL, Stone MJ, Cunningham D, Fay J, Newman J, Collins R, et al. A phase I study of an anti-CD22-deglycosylated ricin A chain immunotoxin in treatment of B-cell lymphomas resistant to conventional therapy. Blood. 1993; 82:2624-33. Google Scholar12. Papadopoulos EB, Ladanyi M, Emanuel D, Mackinnon S, Boulad F, Carabasi MH, et al. Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation. N Engl J Med. 1994; 330:1185-91. Google Scholar13. Fischer A, Blanche S, Le Bidois J, Bordigoni P, Garnier J, Niaudet P, et al. Anti-B-cell monoclonal antibodies in the treatment of severe B-cell lymphoproliferative syndrome following bone marrow and organ transplantation. N Engl J Med. 1991; 324:1451-6. Google Scholar14. Leblond V, Sutton L, Dorent R, Davi F, Bitker MO, Gabarre J, et al. Lymphoproliferative disorders after organ transplantation: a report of 24 cases observed in a single center. J Clin Oncol. 1995; 13:961-8. Google Scholar15. Ghetie MA, Richardson J, Tucker T, Jones D, Uhr JW, Vitetta ES. Antitumor activity of Fab and IgG-anti-CD22 immunotoxins in disseminated human B lymphoma grown in mice with severe combined immunodeficiency disease: effect on tumor cells in extranodal sites. Cancer Res. 1991; 51:5876-80. Google Scholar Author, Article, and Disclosure InformationAuthors: Adrian M. Senderowicz, MD; Ellen Vitetta, PhD; Donna Headlee, RN; Victor Ghetie, PhD; Jonathan W. Uhr, MD; William D. Figg, PharmD; Richard M. Lush, PhD; Maryalice Stetler-Stevenson, MD, PhD; Glenn Kershaw, MD; Douglas W. Kingma, MD; Elaine S. Jaffe, MD; Edward A. Sausville, MD, PhDAffiliations: From the National Cancer Institute, National Institutes of Health, Bethesda, Maryland; University of Massachusetts Medical Center, Worcester, Massachusetts; and University of Texas Southwestern Medical Center, Dallas, Texas.Grant Support: Extramural portions of the study were supported by National Institutes of Health grants CA28149 and CA41081.Corresponding Author: Edward A. Sausville, MD, PhD, Developmental Therapeutics Program, National Cancer Institute, Executive Plaza North, Suite 843, 6130 Executive Boulevard, Rockville, MD 20852.Current Author Addresses: Dr. Senderowicz and Ms. Headlee: Medicine Branch, Division of Clinical Science, National Cancer Institute, National Institutes of Health, Building 10, Room 12N226, 9000 Rockville Pike, Bethesda, MD 20892. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byBL22: A Milestone in Targeting CD22Ribosome-inactivating Proteins in Cancer TreatmentRecombinant ImmunotoxinsLymphoma in Other DiseasesAntibody-targeted therapyPost-transplant lymphoproliferative disorders following solid-organ transplantationGeneration of Stably Transfected Eukaryotic Cell Lines Producing ImmunoRNAse Fusion ProteinsTransition state analogues in structures of ricin and saporin ribosome-inactivating proteinsHigh-Level Production of a Humanized ImmunoRNase Fusion Protein from Stably Transfected Myeloma CellsImmunotoxinsRecombinant Immunotoxins Containing Truncated Bacterial Toxins for the Treatment of Hematologic MalignanciesPost-transplant lymphoproliferative disorder treated with rituximab: case reportBL22 and lymphoid malignanciesImmunotoxins in the Treatment of Refractory Hairy Cell LeukemiaImmunotoxins and Recombinant Immunotoxins in Cancer TherapyImmunotoxins for targeted cancer therapyRituximab therapy is effective for posttransplant lymphoproliferative disorders after solid organ transplantationA Dimeric Angiogenin Immunofusion Protein Mediates Selective Toxicity Toward CD22+ Tumor CellsTargeting malignant B-cell lymphoma with a humanized anti-CD22 scFv-angiogenin immunoenzymeRibonucleases as a Novel Pro-Apoptotic Anticancer Strategy: Review of the Preclinical and Clinical Data for RanpirnaseRecombinant immunotoxins for the treatment of haematological malignanciesImmunotoxin therapy of hematologic malignanciesAntibodies for the treatment of diffuse large cell lymphomaGenetic engineering of an immunotoxin to eliminate pulmonary vascular leak in miceImmunobiological treatments of hairy-cell leukaemiaImmunotoxinsSustained remission of an extensive monoclonal, Epstein-Barr virus-associated diffuse large B cell lymphoma in a kidney-pancreas transplant recipientIdentification of ricin A-chain HLA class II-restricted epitopes by human T-cell clonesEffects of specific anti-B and/or anti-plasma cell immunotherapy on antibody production in baboons: depletion of CD20- and CD22-positive B cells does not result in significantly decreased production of anti-αGal antibodyTreatment of post-transplant lymphoproliferative disorder with monoclonal cd20 antibody (rituximab) after heart transplantationPotent and specific antitumor effects of an anti-CD22–targeted cytotoxic ribonuclease: potential for the treatment of non-Hodgkin lymphomaRecombinant immunotoxins in targeted cancer cell therapyCD-20 expression in post-transplant lymphoproliferative disorders: Treatment with RituximabImmunotoxinsA combination of anti-CD3 and anti-CD7 ricin A-immunotoxins for the in vivo treatment of acute graft versus host diseaseA combination of anti-CD3 and anti-CD7 ricin A-immunotoxins for the in vivo treatment of acute graft versus host diseasePost-transplantation lymphoproliferative disorders: advances in diagnosis, prevention and management in childrenSelection and expansion of T cells from untreated patients with CLL: source of cells for immune reconstitution?Chimeric toxins in cancer treatmentPost-Transplant MalignancyRelationship of the CD22 Immunotoxin Dose and the Tumour Establishment in a SCID Mice ModelTreatment of post-transplant lymphoproliferative disease with rituximab monoclonal antibody after lung transplantationImmunotoxins in cancer therapyComplete regression of human B-cell lymphoma xenografts in mice treated with recombinant anti-CD22 immunotoxin RFB4(dsFv)-PE38 at doses tolerated by cynomolgus monkeysClinical and pathological features of post-transplant lymphoproliferative disorders (PTLD)Evaluation of immunotoxins containing single-chain ribosome-inactivating proteins and an anti-CD22 monoclonal antibody (OM124): in vitro and in vivo studiesConclusionsSELECTIVE OUTGROWTH OF A POSTTRANSPLANT B-IMMUNOBLASTIC LYMPHOMA EXPRESSING A LATENT MEMBRANE PROTEIN-1 DELETION VARIANT1 1 June 1997Volume 126, Issue 11Page: 882-885KeywordsAntigensAttentionB cellsBiopsyChemotherapyClinical pathologyEpstein-Barr virusLymphomaRenal transplantationToxins ePublished: 15 August 2000 Issue Published: 1 June 1997 Copyright & PermissionsCopyright © 1997 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...